BJMO - volume 11, issue 3, may 2017
D. Schrijvers MD, PhD, T. Debacker MD
The characteristics of carcinogenesis are discussed in relation to prostate cancer. Some of these are already used as treatment targets in daily clinical practice, while in some, medications proved to be ineffective to interfere with these mechanisms of carcinogenesis.
Currently, treatments that have shown efficacy are addressing the mechanism of sustained proliferative activity, while there are some indications that immune modulation and agents interfering with DNA repair may play a role in the treatment of prostate cancer.
Other aspects of carcinogenesis need more study in patients with prostate cancer to show a benefit and they must be the scope of future research.
(BELG J MED ONCOL 2017;11(3):87–91)
Read moreBJMO - 2017, issue 3, february 2017
B. De Laere PhD, P. Van Oyen , C. Ghysel , P. Ost MD, PhD, Wim Demey MD, L. Hoekx MD, D. Schrijvers MD, PhD, B. Brouwers MD, PhD, W. Lybaert MD, E. Everaert , J. Ampe , P. Van Kerckhove , D. De Maeseneer MD, M. Strijbos MD, PhD, A. Bols MD, PhD, K. Fransis , S. Oeyen , V. Van Dam , A. Brouwer , G. Van Den Eynden MD, PhD, A. Rutten MD, J. Vandebroek , S. Van Laere PhD, L. Dirix MD
BJMO - volume 9, issue 5, september 2015
D. Schrijvers MD, PhD, W. Teurfs MD
Docetaxel has shown to improve survival and quality of life in patients with castration-resistant prostate cancer. Its place as first-line treatment in this population is challenged by new hormonal treatments, but it still has a place in this setting. Its role in metastatic hormone-sensitive prostate cancer is becoming clearer and docetaxel may be offered to selected patients. In localised high-risk prostate cancer the place of docetaxel remains to be determined.
(BELG J MED ONCOL 2015;9(5):191–93)
Read moreBJMO - volume 9, issue 3, july 2015
D. Schrijvers MD, PhD, N. Toussaint MD, C. Goor MD, T. Debacker MD
In this case report we describe the incidental finding of prostate cancer in a patient undergoing a transurethral prostate resection for benign prostatic hyperplasia and discuss the diagnostic and treatment approach of this patient group.
(BELG J MED ONCOL 2015;9(3):104–6)
Read moreBJMO - volume 9, issue 3, july 2015
T. Vermassen PhD, P. de Visschere MD, G. Villeirs MD, PhD, D. Schrijvers MD, PhD, S. Rottey MD, PhD
Due to the success of last year, a second national Belgian multidisciplinary scientific meeting on urological cancers was held with the cooperation of medical oncologists (BSMO), urologists (BAU) and radiation oncologists (ABRO/BVRO). It was a great opportunity to build bridges between these three important specialisations involved in the treatment of urological cancers.
The steering committee of the meeting consisted of J. P. Machiels, G. Pelgrims, S. Rottey (members of BSMO); L. Hoekx, S. Joniau, T. Roumeguere (members of BAU); O. De Hertogh, G. De Meerleer and Y. Neybuch (members of ABRO/BVRO). The second meeting, held in Brussels on March 28th, 2015 was a great success with more than 100 attendees of the different specialisations involved.
In this meeting report you will find summaries of the lectures of Dr De Visschere (Radiologist) and Dr Schrijvers (Medical Oncologist).
(BELG J MED ONCOL 2015;9(3):113–16)
Read moreBJMO - volume 9, issue 2, may 2015
D. Schrijvers MD, PhD
The androgen receptor plays a role as a nuclear transcription factor after activation by its ligands. It is an essential component in the development and progression of prostate cancer. The different factors that play a role in relation to the androgen receptor and prostate cancer are discussed. The different treatment strategies in relation to prostate cancer are addressed.
(BELG J MED ONCOL 2015;9(2):61–4)
Read moreBJMO - volume 8, issue 4, september 2014
D. Schrijvers MD, PhD, T. Debacker MD
Biomarkers and genomics are making their entrance in daily clinical practice in many tumour types. In prostate cancer, their use is relatively limited. This article reviews biomarkers and genomics used in different clinical settings such as screening, diagnosis, prognosis, prediction and surrogate endpoints for overall survival and shows an unmet need in prostate cancer.
(BELG J MED ONCOL 2014;8(4):104–8)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
